SCHEDULE: Velibor Krstic Increases Stake in Strata Critical Medical

Investor Velibor Krstic has increased his stake in Strata Critical Medical warrants to 16.21% and is calling for a mandatory exchange to prevent expiration.

Summary

• Reporting person Velibor Krstic now holds 1,485,877 warrants of Strata Critical Medical, Inc., representing 16.21% of the public warrants outstanding.
• The investor acquired these warrants for approximately $25,291 in open market transactions.
• Krstic is advocating for a mandatory exchange of warrants via amendment to the warrant agreement to avoid expiration on May 7, 2026.
• The investor argues that the company's strong financial position, including $14.1 million in 2025 Adjusted EBITDA and $110 million in total liquidity, justifies an exchange rather than allowing the warrants to expire worthless.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-tense situation; while the company's underlying fundamentals are strong, the activist investor's public pressure on the board indicates potential governance friction.

Positives

• The company reported record 2025 results with an Adjusted EBITDA of $14.1 million.
• Management has provided strong 2026 guidance, targeting Adjusted EBITDA between $29 million and $33 million.
• The company maintains a robust liquidity position of $110 million, including $61.2 million in cash and undrawn facilities.
• The company's aircraft fleet remains unencumbered, providing potential asset-backed flexibility.

Negatives

• The warrants are approaching a May 7, 2026, expiration date, creating immediate pressure on the capital structure.
• The investor alleges that board inaction regarding the warrant exchange could be interpreted as a breach of fiduciary duty.
• The warrants are currently trading at a very low valuation, as evidenced by the weighted average purchase price of approximately $0.017 per warrant.

Risks

• Potential for the warrants to expire worthless on May 7, 2026, if no amendment or exchange is reached.
• Reliance on the board of directors to act on the proposed mandatory exchange.
• Market volatility affecting the underlying common stock (SRTA) price.

Future Outlook

Management has set a 2026 Adjusted EBITDA target of $29 million to $33 million, signaling an expected growth rate of over 30%.

Management Comments

• The investor states that a Mandatory Exchange via Amendment is the only rational solution to stabilize the capital structure before the May 7, 2026, expiration.
• The investor asserts that inaction by the Board would be interpreted as a premeditated destruction of value and a breach of fiduciary duty.

Industry Context

StockSavvy.ai notes that this filing highlights the aggressive activism often seen in the transplant logistics sector, where companies with high growth potential and complex capital structures (warrants/SPAC-related instruments) face pressure to optimize their balance sheets before equity instruments expire.

Comparison to Industry Standards

• The company's reported 30% growth target is aggressive compared to broader logistics industry benchmarks.
• The use of warrant amendments to avoid expiration is a common, albeit contentious, strategy in post-SPAC corporate governance.

Corporate Governance

Stakeholder Impact

• Shareholders may see dilution or changes in warrant value depending on the outcome of the proposed exchange.
• The board faces pressure to address the capital structure to avoid allegations of breach of fiduciary duty.

Next Steps

• Potential board response to the investor's call for a warrant exchange.
• Possible solicitation of written consent from other shareholders to reach the 50% threshold.
• Warrant expiration deadline on May 7, 2026.

Key Dates

Recommendation

The stock is currently in a state of governance uncertainty due to the activist investor's public pressure. Investors should hold until the board clarifies its stance on the warrant exchange, as the outcome will significantly impact the company's capital structure and potential dilution.

Keywords

Strata Critical Medical, SRTA, Warrants, Schedule 13D, Capital Structure, Transplant Logistics